<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093504</url>
  </required_header>
  <id_info>
    <org_study_id>2021-02</org_study_id>
    <nct_id>NCT05093504</nct_id>
  </id_info>
  <brief_title>Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban &amp; Rivaroxaban (STAR-D)</brief_title>
  <acronym>STAR-D</acronym>
  <official_title>Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban &amp; Rivaroxaban (STAR-D): A Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of&#xD;
      Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing&#xD;
      Urgent Cardiothoracic Surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of perioperative bleeding</measure>
    <time_frame>Through the first 48 hours post-operation</time_frame>
    <description>Incidence of clinically significant perioperative bleeding events, as evaluated by a ranked composite endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOAC drug removal: apixaban</measure>
    <time_frame>Through 30 minutes post-CPB</time_frame>
    <description>Change in blood apixaban levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOAC drug removal: rivaroxaban</measure>
    <time_frame>Through 30 minutes post-CPB</time_frame>
    <description>Change in blood rivaroxaban levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest tube drainage</measure>
    <time_frame>Through 24 hours post-operation</time_frame>
    <description>Drainage volume from all chest and mediastinal tubes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusions (volume)</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>Total platelet transfusions (mL) during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusions (units)</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>Total platelet transfusions (units) during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRBC transfusions (volume)</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>Total PRBC transfusions (mL) during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRBC transfusions (units)</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>Total PRBC transfusions (units) during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate, severe, and massive perioperative bleeding events</measure>
    <time_frame>Through the first day post-operation</time_frame>
    <description>Perioperative bleeding events classified according to the Universal Definition of Perioperative Bleeding, and analyzed by class (Class 0, 1, 2, 3, 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical re-exploration for bleeding</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>All surgical re-explorations for excessive bleeding, as adjudicated by an independent CEC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of fatal perioperative bleeding</measure>
    <time_frame>Through to discharge from index hospitalization, on average 1-2 weeks</time_frame>
    <description>Deaths directly attributable to procedure-related bleeding, as adjudicated by an independent CEC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of perioperative bleeding for apixaban subgroup</measure>
    <time_frame>Through the first 48 hours post-operation</time_frame>
    <description>Incidence of clinically significant perioperative bleeding events for the apixaban subgroup, as evaluated by a ranked composite endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of perioperative bleeding for rivaroxaban subgroup</measure>
    <time_frame>Through the first 48 hours post-operation</time_frame>
    <description>Incidence of clinically significant perioperative bleeding events for the apixaban subgroup, as evaluated by a ranked composite endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hemorrhage, Surgical</condition>
  <condition>Hemorrhage Postoperative</condition>
  <condition>Blood Loss, Surgical</condition>
  <condition>Blood Loss, Postoperative</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard of care with Sham set-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DrugSorb-ATR Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care + DrugSorb-ATR system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham comparator</intervention_name>
    <description>Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DrugSorb-ATR system</intervention_name>
    <description>Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit</description>
    <arm_group_label>DrugSorb-ATR Intervention</arm_group_label>
    <other_name>Sorbent hemoperfusion system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age 18 years or older, with documented full, written informed consent&#xD;
&#xD;
          2. Requiring cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB) within 30&#xD;
             hours from last dose of either apixaban or rivaroxaban (*note that patients must be&#xD;
             taking apixaban or rivaroxaban for one of the following indications: a) reduction of&#xD;
             stroke/systemic embolism in nonvalvular atrial fibrillation, or b) initial or extended&#xD;
             treatment of venous thromboembolism)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &gt;30hrs between last apixaban or rivaroxaban dose and start of CT surgery&#xD;
&#xD;
          2. Patients on low dose apixaban or rivaroxaban for prophylactic indications&#xD;
&#xD;
          3. Heart-lung transplant procedures&#xD;
&#xD;
          4. Procedures for ventricular assist device&#xD;
&#xD;
          5. Any of the below conditions that pose a known risk for increased bleeding&#xD;
&#xD;
               1. Heparin induced thrombocytopenia&#xD;
&#xD;
               2. Preoperative platelet count &lt;50,000u/L&#xD;
&#xD;
               3. Hemophelia&#xD;
&#xD;
               4. INR greater than or equal to 1.8&#xD;
&#xD;
          6. Prohibited concomitant antithrombotic medications as defined in the study protocol&#xD;
&#xD;
          7. Acute sickle cell crisis&#xD;
&#xD;
          8. Known allergy to device components&#xD;
&#xD;
          9. Active (untreated) systemic infection&#xD;
&#xD;
         10. History of major organ transplantation and those currently receiving immunosuppressive&#xD;
             medication or who are profoundly immune suppressed&#xD;
&#xD;
         11. Women with positive pregnancy test during current admission or who are breast-feeding&#xD;
&#xD;
         12. Life expectancy &lt;30 days&#xD;
&#xD;
         13. Inability to comply with requirements of the study protocol&#xD;
&#xD;
         14. Treatment with investigational drug or device within 30 days of current surgery&#xD;
&#xD;
         15. Previous enrollment in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Scott &amp; White The Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. M Gibson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, The Baim Institute, and Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Lee, MD</last_name>
    <phone>1-732-482-9995</phone>
    <email>VLee@cytosorbents.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

